China, Oct. 21 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Prospective, Multicenter, Single-Arm Study Evaluating the Efficacy and Safety of Golidocitinib Monotherapy in Patients with Relapsed or Refractory T-Cell Large Granular Lymphocytic Leukemia'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600134749
Registration Time: 2026/10/20
Type: Interventional study
Primary Sponsor: The First Affiliated Hospital, School of Medicine, Zhejiang University
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=341476
Published by HT Digital Content Services with permission from Health Daily Digest....